Objective: To evaluate the clinical significance of high mobility group box
1 (HMGB1) expression in nephridial tissues of lupus nephritis (LN). Methods: Sixty-three
patients with active LN and 15 systemic lupus erythematosus (SLE) (combined without
LN) were included. Renal biopsies were performed in the two groups. The biopsies
were evaluated according to the World Health Organization (WHO) classification and
renal disease activity was estimated using the British Isles lupus assessment group
(BILAG) index. Serum levels of HMGB1 were analyzed by western blot. HMGB1 expression in renal tissue was assessed by immunohistochemistry
in the two groups. The correlation between HMGB1 and renal active index (AI), chronicity
index (CI), pathological type of LN was analyzed. Results: LN biopsies showed WHO class III, IV
or V and all patients had high renal disease activity (BILAG A/B). The HMGB1 expression
was higher in the LN groups than the control groups (t = 9.263, P < 0.05). It showed positive correlation
between HMGB1 expression and SLE DAI classification (r = 0.579, P < 0.05), AI (r = 0.708, P < 0.05) and renal tubule interstitial
(TIL) classification (r = 0.815, P <
0.05), and negative correlation between HMGB1 expression and CI classification (r
= 0.582, P < 0.05). In all patients,
serum levels of HMGB1 increased only slightly inthepatients
References
[1]
Pisetsky, D.S., Erlandsson-Harris, H. and Andersson, U. (2008) High-Mobility Group Box Protein 1 (HMGB1): An Alarmin Mediating the Pathogenesis of Rheumatic Disease. Arthritis Research & Therapy, 10, 1-10.
http://dx.doi.org/10.1186/ar2440
[2]
Yu, M., Wang, H.C., Ding, A.H., Douglas, T., Golenbock, E.L., Czura, C.J., et al. (2006) HMGB1 Signals through Toll-Like Receptor (TLR)4 and TLR2. Shock, 26, 174-179. http://dx.doi.org/10.1097/01.shk.0000225404.51320.82
[3]
Rahman, A. and Isenberg, D.A. (2008) Systemic Lupus Erythematosus. The New England Journal of Medicine, 358, 929-939. http://dx.doi.org/10.1056/NEJMra071297
[4]
Hochberg, M.C. (1997) Updating the American College of Rheumatology Revised Criteria for the Classification of Systemic Lupus Erythematosus. Arthritis Rheumatology, 40, 1725. http://dx.doi.org/10.1002/art.1780400928
[5]
Zickert, A., Palmblad, K., Sundelin, B., Chavan, S., Tracey, K.J., Bruchfeld, A., et al. (2012) Renal Expression and Serum Levels of High Mobility Group Box 1 Protein in Lupus Nephritis. Arthritis Research & Therapy, 14, 1-10.
http://dx.doi.org/10.1186/ar3747
[6]
Isenberg, D.A., Rahman, A., Allen, E., Farewell, V., Akil, M., Bruce, I.N., et al. (2005) BILAG 2004. Development and Initial Validation of an Updated Version of the British Isles Lupus Assessment Group’s Disease Activity Index for Patients with Systemic Lupus Erythematosus. Rheumatology (Oxford), 44, 902-906.
http://dx.doi.org/10.1093/rheumatology/keh624
[7]
Yee, C.S., Farewell, V., Isenberg, D.A., Griffiths, B., The, L.S., Bruce, I.N., et al. (2009) The BILAG-2004 Index Is Sensitive to Change for Assessment of SLE Disease Activity. Rheumatology (Oxford), 48, 691-695.
http://dx.doi.org/10.1093/rheumatology/kep064
[8]
Abdulahad, D.A., Westra, J., Bijzet, J., Limburg, P.C., Kallenberg, C.G. and Bijl, M. (2011) High Mobility Group Box 1 (HMGB1) and Anti-HMGB1 Antibodies and Their Relation to Disease Characteristics in Systemic Lupus Erythematosus. Arthritis Research Therapy, 13, R71. http://dx.doi.org/10.1186/ar3332
[9]
Kruse, K., Janko, C., Urbonaviciute, V., Mierke, C.T., Winkler, T.H., Voll, R.E., et al. (2010) Inefficient Clearance of Dying Cells in Patients with SLE: Anti-dsDNA Autoantibodies, MFG-E8, HMGB-1 and Other Players. Apoptosis, 15, 1098-1113. http://dx.doi.org/10.1007/s10495-010-0478-8
[10]
Pullerits, R., Jonsson, I.-M., Verdrengh, M., Bokarewa, M., Andersson, U., Erlandsson-Harris, H., et al. (2003) High Mobility Group Box Chromosomal Protein 1, a DNA Binding Cytokine, Induces Arthritis. Arthritis Rheumatology, 48, 1693-1700. http://dx.doi.org/10.1002/art.11028
[11]
Yoshizaki, A., Komura, K., Iwata, Y., Ogawa, F., Hara, T. and Muroi, E. (2009) Clinical Significance of Serum HMGB1-1 and Srage Level in Systemic Sclerosis: Association with Disease Severity. Journal of Clinical Immunology, 29, 180-189. http://dx.doi.org/10.1007/s10875-008-9252-x
[12]
Urbonaviciute, V., Fürnrohr, B.G., Meister, S., Munoz, L., Heyder, P., De Marchis, F., et al. (2008) Induction of Inflammatory and Immune Responses by HMGB1-Nucleosome Complexes: Implications for the Pathogenesis of SLE. Journal of Experimental Medicine, 205, 3007-3018. http://dx.doi.org/10.1084/jem.20081165
[13]
Bruchfeld, A., Wendt, M., Bratt, J., Qureshi, A.R., Chavan, S., Tracey, K.J., et al. (2011) High-Mobility Group Box-1 Protein (HMGB1) Is Increased in Antineutrophilic Cytoplasmatic Antibody (ANCA)-Associated Vasculitis with Renal Manifestations. Molecular Medicine, 17, 29-35. http://dx.doi.org/10.2119/molmed.2010.00132
[14]
Kruse, K., Janko, C., Urbonaviciute, V., Mierke, C.T., Winkler, T.H., Voll, R.E., et al. (2010) Inefficient Clearance of Dying Cells In Patients with SLE: Anti-dsDNA Autoantibodies, MFG-E8, HMGB-1 and Other Players. Apoptosis, 15, 1098-1113. http://dx.doi.org/10.1007/s10495-010-0478-8
[15]
Friggeri, A., Banerjee, S., Biswas, S., Freitas, A., Liu, G. and Bierhaus, A. (2011) Participation of the Receptor for Advanced Glycation End Products in Efferocytosis. Journal of Immunology, 186, 6191-6198.
http://dx.doi.org/10.4049/jimmunol.1004134